Business News

Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic Tests

San Diego, California, Hilden, Germany and Germantown, Maryland – October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. The …

Read More »

MSD and 4D Pharma Collaborate to Develop Live Biotherapeutics for Vaccines

LEEDS, England, Oct. 8, 2019 /PRNewswire/ — 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces that the Company has entered into a research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to …

Read More »

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments …

Read More »

Akcea and Pfizer Announce Licensing Agreement for Antisense Therapy being Investigated for Cardiovascular and Metabolic Diseases

BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to …

Read More »

Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

NORTH BILLERICA, Mass. & NEW YORK–(BUSINESS WIRE)–Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial …

Read More »

Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligence

Basel, and Redmond, October 1, 2019 – Novartis today announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The new lab aims to bolster Novartis AI capabilities from research through commercialization and …

Read More »

Numab and Eisai Enter Global Research and Option Agreement to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

TOKYO & ZURICH–(BUSINESS WIRE)–Numab Therapeutics AG (Numab) today announced the initiation of a partnership with Eisai, Co., Ltd (Eisai), under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform. Under the terms of the agreement, Eisai has the option …

Read More »

Servier Acquires Non-Hodgkin B-Cell Lymphoma Treatment Pixuvri from CTI BioPharma

PARIS–(BUSINESS WIRE)–Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI …

Read More »

NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Company Focused on Developing Rare Disease Drugs

AUSTIN, Texas and AMES, Iowa, Sept. 30, 2019 (GLOBE NEWSWIRE) — NewLink Genetics Corporation (NASDAQ:NLNK) and Lumos Pharma, Inc., a private clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare diseases, today announced that the companies have entered into a definitive merger agreement. Under the terms …

Read More »

Illumina and Broad Institute Announce Agreement to Co-Develop Genomic Secondary Analysis Tools

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and the Broad Institute of MIT and Harvard today announced they have entered into a collaboration for the co-development of secondary genomic analysis algorithms and software. Top data scientists from both institutions will collaborate to bring together the industry-leading open-source GATK algorithms with the speed and …

Read More »